ENHANCE-2 (NCT04778397) is investigating the role of magrolimab plus AZA versus Physician’s Choice of VEN-AZA or intensive chemotherapy in patients with TP53 AML in previously untreated AML and ENHANCE-3 (NCT05079230) the role of magrolimab versus placebo in combination with venetoclax and Azacitidine in previously untreated patients with acute myeloid leukemia ineligible for intensive chemotherapy. Here, TP53 is linked to acute myeloid leukemia.